GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avenue Therapeutics Inc (NAS:ATXI) » Definitions » 5-Year Yield-on-Cost %

Avenue Therapeutics (Avenue Therapeutics) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 07, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Avenue Therapeutics 5-Year Yield-on-Cost %?

Avenue Therapeutics's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for Avenue Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



ATXI's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.73
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Avenue Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Avenue Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avenue Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Avenue Therapeutics's 5-Year Yield-on-Cost % falls into.



Avenue Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Avenue Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Avenue Therapeutics  (NAS:ATXI) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Avenue Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Avenue Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Avenue Therapeutics (Avenue Therapeutics) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule for CNS diseases, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
Executives
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
Fortress Biotech, Inc. 10 percent owner 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Invagen Pharmaceuticals, Inc. 10 percent owner SITE B, 7 OSER AVE., HAUPPAUGE NY 11788
Alexandra Maclean officer: Chief Executive Officer C/O AVENUE THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NC 10014
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
David Jin officer: Int. PEO, Int. PFO, and COO C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Joseph Walter Vazzano officer: Chief Financial Officer 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Curtis Gale Oltmans director C/O ARRAY BIOPHARMA INC., 3200 WALNUT ST., BOULDER CO 80301
Jay D Kranzler director 4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO CA 92121
Lucy Lu director, officer: President, CEO THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elizabeth Garrett Ingram director 30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Thomas Gregory Moore director C/O AKORN, INC., 1925 WEST FIELD COURT, SUITE 300, LAKE FOREST IL 60045
Nishant Saxena director CIPLA HOUSE, PENINSULA BUSINESS PARK, LOWER PAREL, MUMBAI K7 400013
Jaideep Ashok Gogtay director CIPLA LTD., MUMBA CENTRAL, BESIDE CITY CENTER, MUMBAI K7 400008